BMEA
Biomea Fusion, Inc. (NASDAQ)
Healthcare — Biotechnology
Biomea Fusion, Inc., a clinical-stage diabetes and obesity medicines company, focuses on the discovery and development of oral drugs to treat patients with diabetes and obesity. It's lead clinical program's drug candidates are COVALENT-111 and COVALENT-112, which has completed Phase II clinical trials of icovamenib for the treatment of Type 1 and Type 2 diabetes; COVALENT-211, which is in Phase II clinical trial of icovamenib for treating insulin-deficient type 2 diabetes; and COVALENT-212, which is in Phase II clinical trial of icovamenib for the treatment of type 2 diabetes. The company is also developing BMF-650, which is in Phase I glucagon-like peptide-131 clinical trial for the treatment of obesity. The company was incorporated in 2017 and is headquartered in San Carlos, California.
Price History
Fundamentals
| Market Cap | $98.33M |
| P/E Ratio (TTM) | - |
| Forward P/E | -1.23 |
| EPS (TTM) | $-0.55 |
| Dividend Yield | - |
| Profit Margin | - |
| Revenue Growth | - |
| ROE | -189.44% |
| Debt/Equity | 6.62 |
| Recommendation | Buy 1.7 |
| Analyst Target | $6.83 |
| Analysts | 6 |
| Indexes | NASDAQ |
Technical Indicators
| RSI (14) | 66.7 |
| Beta | -0.32 |
| SMA 20 | - |
| SMA 40 | - |
| 52-Week High | $2.99 |
| 52-Week Low | $0.87 |
| 50-Day Avg | $1.40 |
| 200-Day Avg | $1.44 |
| Avg Volume | $1.42M |
| Volume | $1.37M |
Performance Analysis
BULLISHBMEA shows predominantly bullish signals based on its fundamentals and technicals.
Recent News
Last updated: Jul 02, 2026 13:00 UTC
Back to Screener Export Report